DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful Phase II clinical study has been conducted with OsteoDex where the result shows high tolerability with mild side effects as well as efficacy and treatment effect on patients who fail on existing drugs. DexTech's goal is to, after completing a phase II study, license each drug candidate. DexTech Medical AB is listed on the Spotlight Stock Market.
View Top Employees from DexTech Medical AB| Website | http://www.dextechmedical.com |
| Revenue | $5 million |
| Employees | 1 (1 on RocketReach) |
| Address | Dag Hammarskjölds Väg 34A, Uppsala, Uppsala 752 37, SE |
| Phone | +46 70 710 47 88 |
| Industry | Drug Manufacturing & Research, Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular DexTech Medical AB employee's phone or email?
DexTech Medical AB Questions
The DexTech Medical AB annual revenue was $5 million in 2023.
1 people are employed at DexTech Medical AB.
DexTech Medical AB is based in Uppsala, Uppsala.
The NAICS codes for DexTech Medical AB are [32541, 3254, 32, 325].
The SIC codes for DexTech Medical AB are [283, 28].
